Clinical Trial · NCT07295171

HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDG

Overview

Typically, PET scans involve an IV injection of 18F-FDG that helps identify cancer. Patients are scanned 60 minutes after injecting 18F-FDG. This study aims to assess the feasibility of a different method of administration - oral ingestion (rather than IV) of 18F-FDG through delayed imaging to identify the optimal time for scanning after consuming the drug. The study will aim to recruit 15-24 individuals who will receive two PET scans - one using delayed oral 18F-FDG imaging and a second regular 18F-FDG. The analysis will focus on establishing a suitable protocol for this administration route while considering patient preference and image quality.

Sponsor

British Columbia Cancer Agency

Phase

N/A

Contacts

Pavithraa Administrative Research Manager

pavithraa.ravi@bccancer.bc.ca

604-877-6000

ClinicalTrials.gov

NCT07295171

Drug / Compound

[18F]FDG

Isotope(s):
Target(s):
  • Glucose Transport